Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
A 13-week preclinical toxicology study of ANA975 aims to explain dose dependence and immune stimulation concerns that led to FDA’s clinical hold for the toll-like receptor agonist.
You may also be interested in...
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion
Anadys, Novartis Pull Plug On Toll-Like Receptor Candidate
Decision does not affect agreement with Novartis to develop TLR7 agonists for hepatitis C and B and other infectious diseases, Anadys CEO tells “The Pink Sheet” DAILY.